 |
Prospector
Profile
07.1275
|
| |
| Genelabs Technologies, Inc. |
NAICS |
541710 |
| 505 Penobscot Drive,
Redwood City, CA 94063 |
Description |
Biotechnology |
| (650) 369-9500 |
Employees |
67 |
| http://www.genelabs.com/ |
Revenue |
(mil) |
11.2090 |
| |
Income |
(mil) |
-8.6850 |
| |
Assets |
(mil) |
22.0720 |
| |
Liability |
(mil) |
19.0660 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Genelabs Technologies, Inc. reported a net loss of $408,000 for the three months ended June 30, 2007, much lower than the $4,297,000 net loss reported during the second quarter of 2006. For the six months ended June 30, 2007, the Company reported a $923,000 net loss, much lower than the $7,687,000 net loss reported in the first half of 2006. The Company's balance sheet showed an accumulated deficit of $238,318,000 at June 30, 2007.
|
| |
|
Intellectual Property:
The active ingredient in Prestara™ is prasterone, more commonly known as dehydroepiandrosterone, or DHEA, which has been in the public domain for many years. Although the Company has an issued U.S. patent on the specific polymorphic form of DHEA used in the formulation of prasterone, the Company does not believe it is possible to obtain patent protection for the base chemical compound anywhere in the world. Genelabs licensed two U.S. patents covering uses of DHEA in treating lupus from Stanford University in 1993. In addition, it has filed patent applications covering additional uses for Prestara™ and various pharmaceutical formulations and intends to file additional applications as appropriate. The Company has filed patent applications covering compounds from its HCV drug discovery programs; however, not all of these HCV applications have issued. A number of patents have been issued to Genelabs covering its drug discovery technologies and methods related to selective regulation of gene expression and the control of viral infections. [SEC Filing S-3 08-16-07]
|
| |
|
Description:
The Company engages in the discovery and development of pharmaceutical products to improve human health.
|
| |
|
Officers:
Irene A. Chow (Chair); James A.D. Smith (Pres., CEO & Acting CFO); Arthur Gray, Jr. (Dir.); Alan Y. Kwan (Dir.); H. H. Haight (Dir.)
|
| |
|
Auditor:
Ernst & Young LLP
|
| |
|
Securities:
Common Stock-Symbol GNLB; NasdaqCM;
30,184,000 common shares outstanding as of July 31, 2007.
|
| |
| |
| |
| return to main page |
|
|
